Canadian biotech strong, driven by small cap players
Rise in small-cap biotech signals return to fundamentals, says Next Edge's Eden Rahim - Cantech Letter
Next Edge Bio-Tech Plus Fund portfolio manager and options strategist Eden Rahim appeared on BNN this morning, explaining how, despite the collapse of the sector’s two headline-grabbing titans, Concordia Healthcare (TSX:CXR, Nasdaq:CXRX) and Valeant Pharmaceuticals (TSX:VRX), the Canadian biotech sector remains aloft, driven by its less famous, under-the-radar small-cap biotech companies. Rahim singled out sterilizer …
Join in on the conversation with Andrew Haller when you subscribe to Toronto Health.